Vicore Pharma Holding AB (VCRE) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−12.1x

Market Cap

$326.29M

MomentumView details →

1D Return

+0.35%

YTD Return

—

RSI (14)

43.5

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−12.1x

Market Cap

$326.29M

RSI (14)

43.5

MomentumView details →

1D Return

+0.35%

YTD Return

—

ProfitabilityView details →

Gross Margin

100.00%

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−309.52%

ROA (TTM)

−284.14%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

−96.51%

EPS CAGR 3Y

−61.79%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

−$0.05

EPS Surprise

−24.39%

Beats (12Q)

0/12

Next Q EPS Est

−$0.01

Avg Surprise (4Q)

−24.39%

Rev Surprise

283.70%

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

12.68x

Quick Ratio

12.68x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

1.33M

Net Income (TTM)

−272.50M

Op. CF (TTM)

−361.21M

Next earningsNov 5, 2026 →

Latest newsMore news →

Vicore Pharma announced it will present new data on its buloxibutid program at the European Respiratory Society Congress 2026 in Barcelona, Spain, September 5-9, 2026.12d ago

Similar companies

Clinuvel Pharmaceuticals Ltd.CUVL Kingworld Medicines Group Limited01110.HK High Tide Inc.HITI Tycoon Group Holdings Limited03390.HK Satellos Bioscience Inc. Common StockMSLE LifeMD, Inc.LFMD Find similar companies →

Latest newsMore news →

Vicore Pharma announced it will present new data on its buloxibutid program at the European Respiratory Society Congress 2026 in Barcelona, Spain, September 5-9, 2026.12d ago